Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer
NCT00674206Phase 2Terminated
- Sponsor
- Emory University
- Start
- Oct 2008
- Primary completion
- Aug 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin in triple-negative breast cancer (TNBC), sponsored by Emory University. Started Oct 2008; status: terminated.
02
Drugs
oxaliplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00674206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00674206.